Pharming Group N.V. - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 68

Pharming Group N.V. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Pharming Group N.V. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Pharming Group N.V. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Pharming Group N.V. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Pharming Group N.V. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Pharming Group N.V.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Pharming Group N.V.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Pharming Group N.V. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Pharming Group N.V.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Pharming Group N.V..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Pharming Group N.V. and identify potential opportunities in those areas.

List of Tables
List of Figures
Pharming Group N.V. Snapshot
Pharming Group N.V. Overview
Key Information
Key Facts
Pharming Group N.V. – Research and Development Overview
Key Therapeutic Areas
Pharming Group N.V. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pharming Group N.V. – Pipeline Products Glance
Pharming Group N.V. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Pharming Group N.V. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Pharming Group N.V.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Pharming Group N.V. – Drug Profiles
Rhucin
Product Description
Mechanism of Action
R&D Progress
Prodarsan
Product Description
Mechanism of Action
R&D Progress
RhC1INH
Product Description
Mechanism of Action
R&D Progress
DNage Products
Product Description
Mechanism of Action
R&D Progress
hLF
Product Description
Mechanism of Action
R&D Progress
rhCOL
Product Description
Mechanism of Action
R&D Progress
rhFIB
Product Description
Mechanism of Action
R&D Progress
Pharming Group N.V. – Pipeline Analysis
Pharming Group N.V. – Pipeline Products by Therapeutic Class
Pharming Group N.V. Pipeline Products By Target
Pharming Group N.V. – Pipeline Products by Route of Administration
Pharming Group N.V. – Pipeline Products by Molecule Type
Pharming Group N.V. – Recent Pipeline Updates
Pharming Group N.V. – Company Statement
Pharming Group N.V. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 28, 2010: Pharming Receives European Marketing Authorization For Ruconest For Treatment Of Hereditary Angioedema
Oct 05, 2010: Santarus Announces Publication Of RHUCIN Clinical Trial Data In Journal Of Allergy And Clinical Immunology
Aug 25, 2010: Pharming To Submit Rhucin BLA To FDA For Treatment Of Hereditary Angioedema
Jul 06, 2010: Pharming And Sanofi Chimie Sign Manufacturing Agreement For Drug Substance Of Ruconest
Jun 24, 2010: Pharming Receives Positive Opinion From Committee For Medicinal Products For Human Use On Rhucin
May 25, 2010: Pharming Submits D180 Response For Rhucin MAA To EMA Without Clock Stop
Apr 01, 2010: Pharming's C1 Inhibitor Effective In Preventing AMR In Animal Model Of Transplant Rejection
Apr 01, 2010: Pharming's C1 Inhibitor Effective In Preventing AMR In Animal Model Of Transplant Rejection
Apr 01, 2010: Pharming's C1 Inhibitor Effective In Preventing AMR In Animal Model Of Transplant Rejection
Apr 01, 2010: Pharming's C1 Inhibitor Effective In Preventing AMR In Animal Model Of Transplant Rejection
Financial Deals Landscape
Pharming Group N.V., Deals Volume Summary, 2004 to YTD 2010
Pharming Group N.V., Deals Summary By Region, 2004 to YTD 2010
Pharming Group N.V., Deals Summary, 2004 to YTD 2010
Pharming Group N.V. Detailed Deal Summary
Asset Purchase
Pharming Group Acquires Patent Portfolio Of PPL Therapeutics
Acquisition
Pharming Group acquires 55% Stake In ProBio International Holdings
Equity Offering
Pharming Group Completes Private Placement Of $3 Million
Pharming Completes Private Placement Of $5 Million
Pharming Group Completes Private Placement Of $21 Million
Pharming Group Completes Private Placement Of $2.54 Million
Pharming Group Completes Private Placement Of $9.13 Million
Pharming Group Completes Private Placement Of $7.98 Million
Pharming Group Completes Private Placement Of $35.6 Million
Debt Offering
Pharming Group Completes Convertible Debt Financing Of $10.8 Million
Pharming Group Completes Private Placement Of Convertible Bonds Offering For $99.76 Million
Pharming Enters Into Co-Development Agreement With Paul Royalty
Pharming Group Enters Into Research Agreement With NovaThera
Pharming Group Enters Into Agreement With Laboratories del Dr. Esteve
Licensing Agreements
Pharming Group Enters Into Licensing Agreement With Aslan
Pharming Group Enters Into Licensing Agreement With Aslan Group
Pharming Enters Into Licensing Agreement With GTC Biotherapeutics
Pharming Enters Into Licensing Agreement With Eczacibasi Ilac Pazarlama
Pharming Group Enters Into Global Licensing Agreement With Advanced Cell Technology
Pharming Group Enters Into Licensing Agreement With AgResearch
Pharming Group Enters Into Worldwide Licensing Agreement With Infigen
Pharming Enters Into License Agreement With ProBio And Infigen
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• The Saudi Arabia Defense Industry - Competitive Landscape and Strategic Insights to 2017: Market Profile
• Aerospace and Defense Industry - Global Strategic Business Report
• EADS N.V.: Defense Company Profile, SWOT and Financial Report
• eLEARNING - Global Strategic Business Report
• Aerospace and Defence Industry - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Future of the Saudi Arabian Defense Industry - Market Attractiveness, Competitive Landscape and Forecasts to 2018
• AerCap Holdings N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
• The Saudi Arabian Defense Industry: Market Opportunities and Entry Strategies, Analyses and Forecasts to 2017
• The Worldwide Industry & Market Opportunities and forecasts to 2014 for Microwaves Global Military & Space-Related Systems